Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Jillian L. Scavone(Unknown), Luciano J. Costa(University of Alabama at Birmingham), Stephanie Andrews(Moffitt Cancer Center), Julie R. Brahmer(Johns Hopkins University), Frederick L. Locke(Moffitt Cancer Center), Brianna Hoffner(University of Colorado Cancer Center), Bryan J. Schneider(Georgetown University), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David Dunnington(Roswell Park Comprehensive Cancer Center), Marianne Davies(Smilow Cancer Hospital), Olalekan O. Oluwole(Vanderbilt University), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Philippe Armand(Harvard University), Alyse Johnson-Chilla(National Comprehensive Cancer Network), Matthew J. Frigault(Harvard University), Nisha Mohindra(Fox Chase Cancer Center), Christopher Hoimes(Duke Medical Center), Sandip Pravin Patel(University of California San Diego), Mabel Ryder(Mayo Clinic in Arizona), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Anthony J. Olszanski(Fox Chase Cancer Center), Lihua E. Budde(City Of Hope National Medical Center), Matthew A. Lunning(University of Nebraska Medical Center), Marc S. Ernstoff(National Cancer Institute), Yinghong Wang(Hangzhou Center for Disease Control and Prevention), Sunil Reddy(Cancer Institute (WIA)), Momen M. Wahidi(Northwestern University), Bianca Santomasso(Georgetown University), Scott Shofer(Cancer Institute (WIA)), Mario E. Lacouture(Garden City Community College)
Cited by 560
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k